Cargando…
Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors
BACKGROUND: Inactivation of the Hippo pathway promotes Yap nuclear translocation, enabling execution of a transcriptional program that induces tissue growth. Genetic lesions of Hippo intermediates only identify a minority of cancers with illegitimate YAP activation. Yap has been implicated in resist...
Autores principales: | Garcia-Rendueles, Maria E. R., Krishnamoorthy, Gnana, Saqcena, Mahesh, Acuña-Ruiz, Adrian, Revilla, Giovanna, de Stanchina, Elisa, Knauf, Jeffrey A., Lester, Rona, Xu, Bin, Ghossein, Ronald A., Fagin, James A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730579/ https://www.ncbi.nlm.nih.gov/pubmed/36476495 http://dx.doi.org/10.1186/s12943-022-01676-9 |
Ejemplares similares
-
Co-inhibition of SMAD and MAPK signaling enhances (124)I uptake in BRAF-mutant thyroid cancers
por: Luckett, Kathleen A, et al.
Publicado: (2021) -
Cooperative Genomic Lesions in HRAS-Mutant Cancers Predict Resistance to Farnesyltransferase Inhibitors
por: Nigam, Aradhya, et al.
Publicado: (2023) -
Telomerase reactivation induces progression of mouse Braf(V600E)-driven thyroid cancers without telomere lengthening
por: Landa, Iñigo, et al.
Publicado: (2023) -
Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors
por: Marusiak, Anna A., et al.
Publicado: (2014) -
Genetic and Pharmacological Targeting of CSF-1/CSF-1R Inhibits Tumor-Associated Macrophages and Impairs BRAF-Induced Thyroid Cancer Progression
por: Ryder, Mabel, et al.
Publicado: (2013)